Piper Jaffray analyst, Matt O'Brien, sees upside for Novadaq (NASDAQ: NVDQ) from DermACELL and oncology which should enable NVDQ’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE